Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients

Fingolimod was recently approved for use in the United States after two phase III trials confirmed its effectiveness in reducing disease activity in relapsing-remitting multiple sclerosis. These positive results, coupled with the important fact that this is the first oral disease-modifying therapy,...

Descripción completa

Detalles Bibliográficos
Autor principal: Marriott, James J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663606/
https://www.ncbi.nlm.nih.gov/pubmed/23861637
http://dx.doi.org/10.4137/JCNSD.S5120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663606/
https://www.ncbi.nlm.nih.gov/pubmed/23861637
http://dx.doi.org/10.4137/JCNSD.S5120

Ejemplares similares